[#DIV28SUPER] Briefing on Synthetic Opioids: the Science, Pharmacology, & Public Health Challenges

Dear Colleagues,

The Bipartisan Heroin Task Force Chaired by Rep. Tom MacArthur (R-NJ) and Rep. Ann McLane Kuster (D-NH) will be holding a briefing on Monday, February 6^th at 4:00.  Dr. Lisa Marsch has been invited to present data from her NIDA-funded Fentanyl Hot Spot Study and the briefing will be broadcast live on CSPAN so please consider tuning in to virtually cheer Lisa on.  Other presenters include Dr. Nora Volkow, Director of the National Institute on Drug Abuse, Dr. Corey Waller, Legislative Advocacy Committee Chairman of the American Society of Addiction Medicine and Dr. Josh Rising, Director of Health Programs for the Pew Charitable Trusts.

 

Regards,

-geoff

 

Geoffrey K. Mumford, Ph.D| Associate Executive Director for Government Relations Science Directorate | 202.336.6067 | gmumford@apa.org  American Psychological Association www.apa.org   Advancing psychology to benefit society and improve people’s lives

 

 

Re: [#DIV28SUPER] Division 28 Award Winners!

Let’s try that one more time!  2017 award winners!

 

Catherine Stanger, Ph.D.

Associate Professor

Center for Technology and Behavioral Health

Geisel School of Medicine at Dartmouth

Dartmouth College

46 Centerra Parkway

EverGreen Center Suite 300

Suite 300, HB 7255

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-646-7023

Fax 603-448-5335

www.c4tbh.org

 

From: Catherine Stanger
Sent: Tuesday, January 31, 2017 9:20 AM
To: DIV28SUPER@LISTS.APA.ORG
Subject: Division 28 Award Winners!

 

Please join me in congratulating our 2016 Division 28 Award Winners!  We had many excellent candidates nominated in all three categories, and I would like to thank all the nominees and those who nominated them for their participation this year.  Division 28 has an outstanding roster of early career and senior scientists doing excellent work.

Now, for our winners.

 

MED Associates Brady-Schuster Award honors a mid-career or senior scientist (at least 15 years after doctoral degree) who conducts outstanding research underscoring the fundamental importance of behavioral science to psychopharmacology or substance abuse.

This year’s winner is Dorothy Hatsukami, Ph.D. Dr. Hatsukami is Professor of Psychiatry at the University of Minnesota.  Minnesota takes it 2 years in a row! Go Golden Gophers!

 

Young Psychopharmacologist Award honors a young scientist conducting original, meritorious work in psychopharmacology and encourages excellence in research at the interface between the disciplines of pharmacology and psychology.

This year’s winner is James Mahoney, Ph.D.  Dr. Mahoney is Assistant Professor in the Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine.

 

Outstanding Dissertation Award honors the best doctoral dissertation in psychopharmacology and substance abuse. 

This year’s winner is Elizabeth Holly, Ph.D.  Dr. Holly completed her Ph.D. in Experimental Psychology in 2015 at Tufts University, and she is currently a postdoctoral fellow in the Department of Neuroscience at the University of Pennsylvania Perelman School of Medicine.

 

Congratulations to all, and we look forward to your presentations in Washington!

 

Regards,

Cathy Stanger

Division 28 Awards Chair

 

 

Catherine Stanger, Ph.D.

Associate Professor

Center for Technology and Behavioral Health

Geisel School of Medicine at Dartmouth

Dartmouth College

46 Centerra Parkway

EverGreen Center Suite 300

Suite 300, HB 7255

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-646-7023

Fax 603-448-5335

www.c4tbh.org

 

[#DIV28SUPER] Division 28 Award Winners!

Please join me in congratulating our 2016 Division 28 Award Winners!  We had many excellent candidates nominated in all three categories, and I would like to thank all the nominees and those who nominated them for their participation this year.  Division 28 has an outstanding roster of early career and senior scientists doing excellent work.

Now, for our winners.

 

MED Associates Brady-Schuster Award honors a mid-career or senior scientist (at least 15 years after doctoral degree) who conducts outstanding research underscoring the fundamental importance of behavioral science to psychopharmacology or substance abuse.

This year’s winner is Dorothy Hatsukami, Ph.D. Dr. Hatsukami is Professor of Psychiatry at the University of Minnesota.  Minnesota takes it 2 years in a row! Go Golden Gophers!

 

Young Psychopharmacologist Award honors a young scientist conducting original, meritorious work in psychopharmacology and encourages excellence in research at the interface between the disciplines of pharmacology and psychology.

This year’s winner is James Mahoney, Ph.D.  Dr. Mahoney is Assistant Professor in the Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine.

 

Outstanding Dissertation Award honors the best doctoral dissertation in psychopharmacology and substance abuse. 

This year’s winner is Elizabeth Holly, Ph.D.  Dr. Holly completed her Ph.D. in Experimental Psychology in 2015 at Tufts University, and she is currently a postdoctoral fellow in the Department of Neuroscience at the University of Pennsylvania Perelman School of Medicine.

 

Congratulations to all, and we look forward to your presentations in Washington!

 

Regards,

Cathy Stanger

Division 28 Awards Chair

 

 

Catherine Stanger, Ph.D.

Associate Professor

Center for Technology and Behavioral Health

Geisel School of Medicine at Dartmouth

Dartmouth College

46 Centerra Parkway

EverGreen Center Suite 300

Suite 300, HB 7255

Lebanon, NH 03766

Catherine.stanger@dartmouth.edu

Phone 603-646-7023

Fax 603-448-5335

www.c4tbh.org

 

[#DIV28SUPER] Cluster of an Unusual Amnestic Syndrome — Massachusetts, 2012–2016

Tragedies like this sometimes lead to new research tools like MPTP.. if in fact this is attributable to a novel toxicant on the street.  Psychologists should be alert to presentations with striking sudden onset amnesia presentations in their hospitals or clinics:

"...MRI of the head, toxicology screening, and neurologic consultation should be considered in all adults aged ≥18 years with sudden-onset amnesia, particularly in patients with altered consciousness. Advanced laboratory testing, including testing for synthetic opioids (e.g., fentanyl) and their analogues, as well as extraneous substances not assessed in these reported cases, might further clarify an association with substance use..."

Barash JA, Somerville N, DeMaria A Jr.. Cluster of an Unusual Amnestic Syndrome — Massachusetts, 2012–2016. MMWR Morb Mortal Wkly Rep 2017;66:76–79. DOI: http://dx.doi.org/10.15585/mmwr.mm6603a2

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

[#DIV28SUPER] Postdoctoral fellowship

T32 POSTDOCTORAL POSITIONS

Co-Occurring Substance Use and Mental Health Disorders

Geisel School of Medicine at Dartmouth

 

The Geisel School of Medicine at Dartmouth offers a unique postdoctoral training program in a developing area of transdisciplinary/translational research, co-occurring substance use and other mental disorders (COD) http://geiselmed.dartmouth.edu/scd/.  Applicants interested in smoking, electronic cigarettes, and technology-delivered interventions are encouraged to apply.

The philosophy of this program asserts that to effectively impact the problems of addiction and mental illness, one must be fully aware of their co-existence, etiologies, phenomenology, and clinical manifestations. Moreover, knowledge of integrated clinical approaches and the healthcare systems that serve those with co-occurring disorders are necessary to inform the questions to be asked in laboratory, animal and human imaging and clinical research studies. At Dartmouth, six interconnected groups from neuroscience through implementation research, and across multiple departments provide research opportunities in social, behavioral, neurobiological mechanisms, treatment development (psychosocial and pharmacological), technology-assisted treatment and dissemination, and health services  and implementation. Faculty include preeminent national/international leaders in COD, Technology and Behavioral Health, Cannabis/Marijuana, behavioral and pharmacological interventions for addiction, schizophrenia and substance use, impact of media on substance use.  Faculty include PhD and MD investigators with strong histories of training scientists, and a team of support faculty committed to establishing a structured training program in COD. Research teams include neuroscientists, psychopharmacologists, behavioral health technologists, clinical trials and contingency management experts, health services researchers, anthropologists, statisticians, economists, and clinicians. Program faculty lead diverse projects funded by many NIH institutes (NIDA, NIAAA, NIMH, NCI, NCATS and NICHD), and also multiple foundation, Department of Education, and VA supported studies. 

 

Appointment:  Typically 2-3 yrs.  Eligibility: Applicants must have completed their training in psychology, or a related discipline and be U.S. citizens or permanent residents.   Trainees are selected on the basis of scholastic record and commitment to a career in co-occurring disorders research.  Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.  For more information:  Contact Dr. Sarah Pratt (sarah.i.pratt@dartmouth.edu), Dr. Mary Brunette (mary.f.brunette@dartmouth.edu), or Dr. Alan Budney (alan.budney@dartmouth.edu).  To apply: Forward curriculum vitae, statement of research interests, and 3 letters of reference to Brian Goodness, Operations Assistant (Brian.D.Goodness@dartmouth.edu). 

 

 

Alan Budney, Ph.D.

Geisel School of Medicine at Dartmouth

Department of Psychiatry

One Medical Center Drive, HB 7459

Lebanon, NH  03756

Email: alan.j.budney@dartmouth.edu

 

[#DIV28SUPER] Collaborative Perspectives on Addiction meeting March 24-25, 2017

Conference Registration

 

The scientific program includes 2 keynote addresses from leaders in the field, 15 symposia, over 80 poster presentations and two days of clinical skill-building opportunities!

 

Two days of clinical skill-building opportunities!

Mini-workshop #1: Emotion Regulation Training: Helping Clients to Manage Negative Emotions
Presented by Clara M. Bradizza, PhD, Kim Slosman, MS, & Paul R. Stasiewicz, PhD, University at Buffalo. This introductory workshop on Emotion Regulation Training (ERT) will review the ERT intervention, describe its basic components and provide a step-by-step guide on implementing core therapeutic principles of ERT.

 

Mini-Workshop #2: Cognitive Behavior Therapy for Alcohol and Drug

Problems: An Introductory Workshop

Presented by Barbara McCrady, PhD, University of New Mexico. The goal of this workshop is to provide an overview of the CBT approach and basic skills in CBT. The workshop will use active learning techniques and application of workshop material to sample cases.

 

Mini-Workshop #3: Treating Suicidal Thoughts and Behaviors in Adults with Substance Use Disorders (SUDs)

Presented by Mark Ilgen, PhD & Erin Goldman, LMSW, University of Michigan. This workshop will review the cognitive behavioral model for suicidal thoughts and provide descriptions of techniques to specifically target suicidal thoughts and behaviors among those with SUDs.

 

Mini-Workshop #4: Screening, Brief Intervention, and Referral to Treatment: SBIRT in Diverse Practice Settings

Presented by Jessica L. Martin, PhD, M. Dolores Cimini, PhD, & Laura Longo, MS, University at Albany. This workshop will present cutting-edge research and training on integrating screening, brief intervention, and referral to treatment in primary health and mental health care settings.

 

Mini-Workshop #5: Drug Use, Misuse, and Abuse: A Workshop on Recent Advances in Psychopharmacology

Presented by Cecile A. Marczinski, PhD, Northern Kentucky University. The purpose of this workshop is to provide a general audience with an overview of how recreational drugs

affect the brain and behavior and can lead to addiction. In addition, the current medications being used to effectively treat addiction will be highlighted.

 

Up to 12 credits of Continuing Education will be available!  Please visit our website for more information.

[#DIV28SUPER] Seeking Nominees for Division 28 President (2019), Council Rep, and Member-at-Large

Hello all,

I would like to ask your help in identifying potential nominees for the above referenced elected positions.  The position of Division president is a one year term for the 2019 calendar year, preceded by a year on the executive committee as President elect and followed by a year as past-president.  The term for the Council Representative is three years as is that of the Member-at-Large. Nominees for President and Council Representative must have Fellow status, but nominees for Member-at-Large do not.

I greatly appreciate your assistance in identifying qualified nominees for these positions. With your help we will continue to have a stellar executive committee to maintain the important contributions made by our Division.

Sincerely,

David S. Festinger, Ph.D.

2017 President

APA Division of Psychopharmacology and Substance Abuse

PCOM provides email capability to all students, faculty, staff, and administration.  All emails and attached files transmitted between and among the foregoing are considered confidential. The emails and attached files are intended solely for the use of the individual or entity to which they are addressed and reading, disclosing, disseminating, distributing or copying by a recipient other than that named therein is strictly prohibited. Any email described herein that is received by an entity or individual to which it is not specifically addressed should be immediately deleted by the unnamed recipient.

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28